文献速递神经肿瘤神经重症

高敏C反应蛋白与白细胞介素-6在胶质瘤和脑膜瘤患者中的预后作用

Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients.
PubMed 文献 · J Neurooncol · 2018-02-19

这项前瞻性队列研究纳入163例接受手术的脑膜瘤、高级别胶质瘤和低级别胶质瘤患者,入院24小时内检测血清IL-6和hsCRP。校正组织学诊断、年龄和性别后,IL-6升高与出院不良结局相关(OR 2.39,95%CI 0.97-5.91,p=0.05);IL-6升高与高级别胶质瘤患者死亡风险增加相关,hsCRP升高与脑膜瘤患者死亡风险增加相关。

要点

  • IL-6升高(≥2 pg/ml)见于25%的脑肿瘤患者,hsCRP升高(≥1 mg/l)见于35%。
  • 校正组织学诊断、年龄和性别后,IL-6升高与出院不良结局相关(OR 2.39,95%CI 0.97-5.91,p=0.05)。
  • 校正年龄、性别、肿瘤切除范围和辅助治疗后,IL-6升高与高级别胶质瘤患者死亡风险增加相关(OR 2.623,95%CI 1.129-5.597,p=0.01);hsCRP升高与脑膜瘤患者死亡风险增加相关(OR 3.650,95%CI 1.038-12.831,p=0.04)。

核心结论

  • IL-6升高与脑肿瘤患者出院不良结局风险增加相关,并与高级别胶质瘤患者死亡风险增加相关;hsCRP升高与脑膜瘤患者死亡风险增加相关。

研究设计与样本

  • 前瞻性队列研究,纳入163例因脑膜瘤(n=94)、高级别胶质瘤(n=48)和低级别胶质瘤(n=21)接受手术的患者,其中女性115例,中位年龄57岁。
  • 入院24小时内采集血清样本,随访持续至2016年11月,出院结局采用格拉斯哥结局量表评估(不良结局=评分1至3分)。

主要发现

  • IL-6升高(≥2 pg/ml)和hsCRP升高(≥1 mg/l)分别见于25%和35%的脑肿瘤患者。
  • 校正脑肿瘤组织学诊断、患者年龄和性别后,IL-6升高与出院不良结局相关(OR 2.39,95%CI 0.97-5.91,p=0.05);hsCRP升高与出院结局无显著关联(p=0.13)。
  • 校正患者年龄、性别、肿瘤切除范围和辅助治疗后,IL-6升高与高级别胶质瘤患者死亡风险增加相关(OR 2.623,95%CI 1.129-5.597,p=0.01);hsCRP升高与脑膜瘤患者死亡风险增加相关(OR 3.650,95%CI 1.038-12.831,p=0.04)。

关键数值与推荐

  • IL-6升高定义为≥2 pg/ml,hsCRP升高定义为≥1 mg/l。
  • 出院不良结局定义为格拉斯哥结局量表评分1至3分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) can be important prognostic indicators of brain tumor patients. We investigated the association of circulating IL-6 and hsCRP concentrations with discharge outcomes and survival of glioma and meningioma patients. One-hundred and sixty-three (115 women; median age 57 years) patients admitted for meningioma (n = 94), high-grade glioma (n = 48) and low-grade glioma (n = 21) surgery were enrolled in this prospective cohort study. Serum samples were collected within 24 h of admission. Discharge outcome was evaluated using the Glasgow Outcome Scale (unfavorable outcome = score from 1 to 3). Follow-up continued until November, 2016. Elevated IL-6 (≥ 2 pg/ml) and hsCRP (≥ 1 mg/l) concentrations were present in 25 and 35% of brain tumor patients, respectively. Elevated IL-6 concentrations were associated with unfavorable outcome at hospital discharge, adjusting for brain tumor histological diagnosis, patient age and gender (OR 2.39, 95% CI 0.97-5.91, p = 0.05). Elevated hsCRP concentrations were not associated with discharge outcome (p = 0.13). In multivariate Cox regression analyses adjusted for patient age, gender, extent of tumor resection and adjuvant treatment, elevated IL-6 concentration was associated with greater mortality risk in high-grade glioma patients (OR 2.623; 95% CI 1.129-5.597; p = 0.01), while elevated hsCRP concentration was associated with greater mortality risk in meningioma patients (OR 3.650; 95% CI 1.038-12.831; p = 0.04). Elevated IL-6 concentration is associated with greater unfavorable outcome risk in brain tumor patients and with greater mortality in high-grade glioma patients, while elevated hsCRP concentration is associated with greater mortality in meningioma patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bunevicius A, Radziunas A, Tamasauskas S, et al. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients. J Neurooncol. 2018. PMID: 29460097. doi:10.1007/s11060-018-2803-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。